Vascular endothelial growth factor (VEGF) pathway and neuroendocrine neoplasms (NENs): prognostic and therapeutic considerations
Published 2014 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Vascular endothelial growth factor (VEGF) pathway and neuroendocrine neoplasms (NENs): prognostic and therapeutic considerations
Authors
Keywords
Neuroendocrine neoplasms, VEGF, Bevacizumab, Sunitinib
Journal
TUMOR BIOLOGY
Volume 35, Issue 11, Pages 10615-10625
Publisher
Springer Nature
Online
2014-09-18
DOI
10.1007/s13277-014-2612-7
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Targeting vascular endothelial growth factor (VEGF) pathway in gastric cancer: Preclinical and clinical aspects
- (2015) Omar Abdel-Rahman CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- Bevacizumab plus octreotide and metronomic capecitabine in patients with metastatic well-to-moderately differentiated neuroendocrine tumors: the xelbevoct study
- (2014) Alfredo Berruti et al. BMC CANCER
- Risk of cardiovascular toxicities in patients with solid tumors treated with sunitinib, axitinib, cediranib or regorafenib: An updated systematic review and comparative meta-analysis
- (2014) Omar Abdel-Rahman et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- Risk of thyroid dysfunction in patients with solid tumors treated with VEGF receptor tyrosine kinase inhibitors: a critical literature review and meta analysis
- (2014) Omar Abdel-Rahman et al. Expert Review of Anticancer Therapy
- In vivo RAF signal transduction as a potential biomarker for sorafenib efficacy in patients with neuroendocrine tumours
- (2013) M Quintela-Fandino et al. BRITISH JOURNAL OF CANCER
- Phase II study of pazopanib monotherapy in metastatic gastroenteropancreatic neuroendocrine tumours
- (2013) H K Ahn et al. BRITISH JOURNAL OF CANCER
- An expression signature of the angiogenic response in gastrointestinal neuroendocrine tumours: correlation with tumour phenotype and survival outcomes
- (2013) D J Pinato et al. BRITISH JOURNAL OF CANCER
- The VEGF pathway in lung cancer
- (2013) Michalis Alevizakos et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Phase I study of sorafenib in combination with everolimus (RAD001) in patients with advanced neuroendocrine tumors
- (2013) Jennifer A. Chan et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Sorafenib and bevacizumab combination targeted therapy in advanced neuroendocrine tumour: A phase II study of Spanish Neuroendocrine Tumour Group (GETNE0801)
- (2013) Daniel Castellano et al. EUROPEAN JOURNAL OF CANCER
- Cabozantinib in Progressive Medullary Thyroid Cancer
- (2013) Rossella Elisei et al. JOURNAL OF CLINICAL ONCOLOGY
- A phase II clinical trial of sunitinib following hepatic transarterial embolization for metastatic neuroendocrine tumors
- (2012) J. R. Strosberg et al. ANNALS OF ONCOLOGY
- Function of Members of the Neuropilin Family as Essential Pleiotropic Cell Surface Receptors
- (2012) Matthew W. Parker et al. BIOCHEMISTRY
- Combination treatment with metronomic temozolomide, bevacizumab and long-acting octreotide for malignant neuroendocrine tumours
- (2012) Anna Koumarianou et al. ENDOCRINE-RELATED CANCER
- Prospective Study of Bevacizumab Plus Temozolomide in Patients With Advanced Neuroendocrine Tumors
- (2012) Jennifer A. Chan et al. JOURNAL OF CLINICAL ONCOLOGY
- Autocrine VEGF–VEGFR2–Neuropilin-1 signaling promotes glioma stem-like cell viability and tumor growth
- (2012) Petra Hamerlik et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Suppression of Tumor Invasion and Metastasis by Concurrent Inhibition of c-Met and VEGF Signaling in Pancreatic Neuroendocrine Tumors
- (2012) Barbara Sennino et al. Cancer Discovery
- Perfusion CT Findings in Patients With Metastatic Carcinoid Tumors Undergoing Bevacizumab and Interferon Therapy
- (2011) Chaan S. Ng et al. AMERICAN JOURNAL OF ROENTGENOLOGY
- Brivanib, a Dual FGF/VEGF Inhibitor, Is Active Both First and Second Line against Mouse Pancreatic Neuroendocrine Tumors Developing Adaptive/Evasive Resistance to VEGF Inhibition
- (2011) Elizabeth Allen et al. CLINICAL CANCER RESEARCH
- Classification and pathology of gastroenteropancreatic neuroendocrine neoplasms
- (2011) Günter Klöppel ENDOCRINE-RELATED CANCER
- Activity of XL184 (Cabozantinib), an Oral Tyrosine Kinase Inhibitor, in Patients With Medullary Thyroid Cancer
- (2011) Razelle Kurzrock et al. JOURNAL OF CLINICAL ONCOLOGY
- Vandetanib in Patients With Locally Advanced or Metastatic Medullary Thyroid Cancer: A Randomized, Double-Blind Phase III Trial
- (2011) Samuel A. Wells et al. JOURNAL OF CLINICAL ONCOLOGY
- Neuroendocrine neoplasms of the gut and pancreas: new insights
- (2011) Guido Rindi et al. Nature Reviews Endocrinology
- Sunitinib Malate for the Treatment of Pancreatic Neuroendocrine Tumors
- (2011) Eric Raymond et al. NEW ENGLAND JOURNAL OF MEDICINE
- Insights into Angiogenesis in Non-Small Cell Lung Cancer: Molecular Mechanisms, Polymorphic Genes, and Targeted Therapies
- (2011) Ramon Andrade de Mello et al. Recent Patents on Anti-Cancer Drug Discovery
- The pathological diagnosis of neuroendocrine tumors: common questions and tentative answers
- (2011) Marco Volante et al. VIRCHOWS ARCHIV
- Angiogenic markers endoglin and vascular endothelial growth factor in gastroenteropancreatic neuroendocrine tumors
- (2011) Patricia Kuiper WORLD JOURNAL OF GASTROENTEROLOGY
- A prospective phase II study of 2-methoxyestradiol administered in combination with bevacizumab in patients with metastatic carcinoid tumors
- (2010) Matthew H. Kulke et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Autocrine VEGF Signaling Synergizes with EGFR in Tumor Cells to Promote Epithelial Cancer Development
- (2010) Beate M. Lichtenberger et al. CELL
- VEGFR-2 expression in carcinoid cancer cells and its role in tumor growth and metastasis
- (2010) Scott R. Silva et al. INTERNATIONAL JOURNAL OF CANCER
- Phase II Clinical Trial of Sorafenib in Metastatic Medullary Thyroid Cancer
- (2010) Elaine T. Lam et al. JOURNAL OF CLINICAL ONCOLOGY
- Vandetanib for the Treatment of Patients With Locally Advanced or Metastatic Hereditary Medullary Thyroid Cancer
- (2010) Samuel A. Wells et al. JOURNAL OF CLINICAL ONCOLOGY
- Placebo-Controlled, Double-Blind, Prospective, Randomized Study on the Effect of Octreotide LAR in the Control of Tumor Growth in Patients With Metastatic Neuroendocrine Midgut Tumors: A Report From the PROMID Study Group
- (2009) Anja Rinke et al. JOURNAL OF CLINICAL ONCOLOGY
- The oral multitarget tumour growth inhibitor, ZK 304709, inhibits growth of pancreatic neuroendocrine tumours in an orthotopic mouse model
- (2008) A Scholz et al. GUT
- Targeting Vascular Endothelial Growth Factor in Advanced Carcinoid Tumor: A Random Assignment Phase II Study of Depot Octreotide With Bevacizumab and Pegylated Interferon Alfa-2b
- (2008) James C. Yao et al. JOURNAL OF CLINICAL ONCOLOGY
- One Hundred Years After “Carcinoid”: Epidemiology of and Prognostic Factors for Neuroendocrine Tumors in 35,825 Cases in the United States
- (2008) James C. Yao et al. JOURNAL OF CLINICAL ONCOLOGY
- Activity of Sunitinib in Patients With Advanced Neuroendocrine Tumors
- (2008) Matthew H. Kulke et al. JOURNAL OF CLINICAL ONCOLOGY
- Angiogenesis and Tumor Progression in Neuroendocrine Digestive Tumors
- (2008) Gilles Poncet et al. JOURNAL OF SURGICAL RESEARCH
- Priorities for Improving the Management of Gastroenteropancreatic Neuroendocrine Tumors
- (2008) Irvin M. Modlin et al. JNCI-Journal of the National Cancer Institute
- Gastroenteropancreatic neuroendocrine tumours
- (2008) Irvin M Modlin et al. LANCET ONCOLOGY
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started